Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
Kamlesh Khunti, Serge Jabbour, Xavier Cos, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 7, pp. 1187-1196
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
Christine P. Limonte, Yoshio N. Hall, Subbulaxmi Trikudanathan, et al.
Journal of Diabetes and its Complications (2022) Vol. 36, Iss. 6, pp. 108204-108204
Open Access | Times Cited: 32
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease
Robert Nee, Christina M. Yuan, Andrew S. Narva, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 3, pp. 532-541
Open Access | Times Cited: 31
Advances in secondary prevention mechanisms of macrovascular complications in type 2 diabetes mellitus patients: a comprehensive review
Huifang Guan, Jiaxing Tian, Ying Wang, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 6
Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners
Pamela Kushner, Kamlesh Khunti, Ana Cebrián, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3757-3770
Open Access | Times Cited: 6
SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
Naser Safaie, Shahab Masoumi, Shaban Alizadeh, et al.
Cell Biochemistry and Function (2024) Vol. 42, Iss. 1
Closed Access | Times Cited: 5
The prevalence of cardiovascular diseases, chronic kidney disease, and obesity in patients with type 2 diabetes mellitus and the description of concurrent treatments: A two-center retrospective cross-sectional study in Saudi Arabia
Omar A. Alshaya, Ghazwa B. Korayem, Munirah Alghwainm, et al.
Saudi Pharmaceutical Journal (2024) Vol. 32, Iss. 5, pp. 102054-102054
Open Access | Times Cited: 4
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 4
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial.
Nancy Haff, Daniel M. Horn, Gauri Bhatkhande, et al.
American Heart Journal (2025)
Closed Access
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
André Scheen
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1053-1062
Closed Access | Times Cited: 8
Rising to the challenge of cardio-renal-metabolic disease in the 21st century: Translating evidence into best clinical practice to prevent and manage atherosclerosis
Andrew J. Krentz, Stephan Jacob, Christian Heiß, et al.
Atherosclerosis (2024) Vol. 396, pp. 118528-118528
Closed Access | Times Cited: 2
The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study
Ghazwa B. Korayem, Omar A. Alshaya, Albandari A. Alghamdi, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 10
Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes
Joshua J. Neumiller, Wendy L. St. Peter, Jay H. Shubrook
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1367-1367
Open Access | Times Cited: 1
A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor
Ling Song, Xiaoxu Wang, Jingfang Sun, et al.
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 3, pp. 505-518
Closed Access | Times Cited: 3
The Reasons for Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects – a Family Doctor Perspective: Does Limited Applicability of Clinical Guidelines in Real-Life Practice Matter? A Narrative Review
Tomislav Kurevija, Dunja Šojat, Zvonimir Bosnić, et al.
(2024)
Open Access
The Reasons for the Low Uptake of New Antidiabetic Drugs with Cardiovascular Effects—A Family Doctor Perspective
Tomislav Kurevija, Dunja Šojat, Zvonimir Bosnić, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 6, pp. 1617-1617
Open Access
Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022
Tamara Y. Milder, Jialing Lin, Sallie‐Anne Pearson, et al.
British Journal of Clinical Pharmacology (2024)
Open Access
Cost-Effectiveness of Empagliflozin in Chronic Kidney Disease with or without Albuminuria
Motoki Odawara, Hiroshi Nishi, Satoshi Kodera, et al.
Clinical Journal of the American Society of Nephrology (2024) Vol. 20, Iss. 1, pp. 50-61
Closed Access
Bexagliflozin in type 2 diabetes: a profile of its use
Nicole L. France, Matt Shirley
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 7, pp. 241-249
Closed Access
Managing drug therapy-related problems and assessment of chronic diabetic wounds
Maria Infant Majula Shifani Mahendran, Vinoj Gopalakrishnan, V. Saravanan, et al.
Current Medical Research and Opinion (2024), pp. 1-17
Closed Access
Glucosuria as a major mechanism-associated effect of sodium-glucose cotransporter 2 inhibitors: Is there cause for concern?
T. Yu. Demidova, M. Ya. Izmaylova
Meditsinskiy sovet = Medical Council (2024), Iss. 16, pp. 172-182
Open Access
Sodium–Glucose Cotransporter-2 Inhibitors and Prevention of Adverse Kidney Outcomes in Type 2 Diabetes: A Clinical Multi-Ethnic Asian Cohort
Liang Feng, Zhong Hong Liew, Yong Mong Bee, et al.
Kidney Medicine (2024), pp. 100963-100963
Open Access
Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors Prescription among Physicians in Saudi Arabia
Mohammed Somaili, Omar Oraibi, Majed Darraj, et al.
Current Diabetes Reviews (2023) Vol. 20, Iss. 4
Closed Access | Times Cited: 1
‘We are somehow fixated on this being a diabetes drug’: a qualitative study exploring the views of cardiologists and nephrologists about sodium‐glucose cotransporter 2 inhibitor initiation
Tamara Y. Milder, Sophie L. Stocker, Melissa T. Baysari, et al.
Internal Medicine Journal (2023) Vol. 54, Iss. 4, pp. 559-567
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top